CASI Pharmaceuticals, Inc.
CASIF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962738
No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding CASI Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 24 | 22 | −2 |
| Shares | 2.25M | 2.61M | +361.8K (+16.1%) |
| Value | $2.65M | $4.33M | +$1.68M (+63.4%) |
New holders (3)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Investments, LP | 33,267 | $55.2K | 0.00% |
| Ground Swell Capital, LLC | 10,135 | $16.8K | 0.04% |
| Group One Trading, L.P. | 2,300 | $3.82K | 0.00% |
Sold out (5)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| ADAR1 Capital Management, LLC | 44,120 | $52.1K |
| Citadel Advisors LLC | 36,246 | $42.8K |
| Two Sigma Securities, LLC | 11,599 | $13.7K |
| Susquehanna International Group, LLP | 10,151 | $12.0K |
| Citigroup Inc | 19 | $22 |